<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949920</url>
  </required_header>
  <id_info>
    <org_study_id>B00544</org_study_id>
    <secondary_id>19/NW/0099</secondary_id>
    <nct_id>NCT03949920</nct_id>
  </id_info>
  <brief_title>A Study of Migalastat in Fabry Disease</brief_title>
  <acronym>GALAFAB</acronym>
  <official_title>A Prospective Observational Study Investigating the Impact of Migalastat on Cardiovascular Structure and Function in Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salford Royal NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fabry disease is a rare metabolic condition characterised by the widespread deposition of
      sphingolipids in multiple organ systems. Cardiac involvement is common, it occurs in fifty
      percent of patients and it is the leading cause of death. Despite this, heart and blood
      vessel (cardiovascular system) manifestations of Fabry disease remain poorly characterised,
      and it remains unclear which patients benefit from therapy, or when therapy should be
      initiated. Migalastat is increasingly used to treat fabry disease however the impact of
      Migalastat on the cardiovascular system is poorly understood. Detailed assessment of the
      impact of Migalastat on heart and blood vessel structure and function is urgently needed.
      This observational study will use state of the art, non-invasive investigations to provide
      greater understanding of the cardiovascular manifestations of Fabry disease and the effects
      of Migalastat. It will provide insight into which patients respond more effectively to
      Migalastat, which in turn will facilitate personalisation of therapy, optimisation of the
      timing of therapy initiation and more cost-effective care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective longitudinal observational study of patients starting Migalastat as
      part of routine care. Participants will be recruited from outpatient clinics and have a
      number of investigations before starting therapy and after twelve months of therapy.

      Investigations will include a detailed assessment of symptoms and clinical features, blood
      tests, echocardiography, detailed cardiac MRI scans, heart rhythm monitoring and exercise
      capacity assessment.

      Parameters will be assessed at baseline and at twelve months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indexed Left Ventricular Mass (grams/m2)</measure>
    <time_frame>12 months</time_frame>
    <description>LV mass, indexed to body surface area, assessed using cardiac MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BSA-indexed LV volumes measured using cardiac MRI, from baseline to 12 months (mls/m2)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change LV ejection fraction, measured using cardiac MRI (%)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial extracellular volume, measured using cardiac MRI (%)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial tissue T1 and T2 times measured using cardiac MRI (ms)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary artery systolic pressure, measured using echocardiography (mmHg)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial PCr/ATP ratio, measured using cardiac MRI spectroscopy (ratio)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of extra heart beats in a 24 hour period, measured using ambulatory heart monitoring. (number)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity - Six minute walk test (meters)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>20. Change in health status (quality of life), measured using change in SF-36 score. (score)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lyso-GB3 blood test levels (nmol/L)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Troponin blood test levels (ng/L)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT pro BNP blood test levels (pg/L)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Fabry Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Migalastat</intervention_name>
    <description>Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants may agree to donating a blood sample that will be stored in a biorepository for
      use in future ethically approved research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Fabry disease commencing Migalastat as part of routine care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Confirmed Fabry disease Aged 16 or over Beginning clinical treatment with Migalastat

        Exclusion Criteria:

        Contraindication to cardiac MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chris Miller, BSc MBChB MRCP PhD</last_name>
    <phone>0161 291 4075</phone>
    <phone_ext>4075</phone_ext>
    <email>christopher.miller@manchester.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Orsborne, BSc MBChB MRCP</last_name>
    <phone>0161 291 4075</phone>
    <phone_ext>4075</phone_ext>
    <email>christopher.orsborne@student.manchester.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Manchester University Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M139LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Miller, BSc, MBChB, PhD, MRCP</last_name>
      <phone>0161 291 4075</phone>
      <phone_ext>4075</phone_ext>
      <email>christopher.miller@manchester.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Chris Orsborne, BSc, MBChB, MRCP</last_name>
      <phone>0161 291 4075</phone>
      <phone_ext>4075</phone_ext>
      <email>christopher.orsborne@manchester.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Chris Orsborne, BSc, MBChB, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Jovanovic</last_name>
      <phone>0161 206 1080</phone>
      <phone_ext>61080</phone_ext>
      <email>Ana.Jovanovic@srft.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karen Wynne</last_name>
      <phone>0161 206 1080</phone>
      <phone_ext>60180</phone_ext>
      <email>karen.wynne@srft.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry</keyword>
  <keyword>Anderson-Fabry</keyword>
  <keyword>Migalastat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

